SCHEMBL2686293

SCHEMBL2686293

COc1ccc2c(c1)c(C(C)C(=O)O)cn2C

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 7/20 0.64
MTNR1B P49286 7/20 0.64
PTGS2 P35354 3/20 0.51
PTGS1 P23219 2/20 0.51
AKR1C3 P42330 2/20 0.51
AKR1C2 P52895 2/20 0.51
CDC42 P60953 1/20 0.51
RAC1 P63000 1/20 0.51
CYP1A2 P05177 1/20 0.51
TSHR P16473 1/20 0.51
SLC22A6 Q4U2R8 1/20 0.51
ABCG2 Q9UNQ0 1/20 0.49
NQO2 P16083 1/20 0.49
KDM4E B2RXH2 1/20 0.47
GAA P10253 1/20 0.47
ADRB2 P07550 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22316063 0.82 MTNR1A (0.61) MTNR1AMTNR1BNQO2KDM4EADRB2
SCHEMBL2688129 0.81 KDM4E (0.43) MTNR1AMTNR1BPTGS2PTGS1KDM4E
SCHEMBL7241953 0.80 KMT2A (0.48) PTGS2PTGS1KDM4E
SCHEMBL11569102 0.77 AKR1C3 (0.65) PTGS2PTGS1AKR1C3AKR1C2CYP1A2
SCHEMBL4406870 0.77 ABCG2 (0.60) MTNR1AMTNR1BTSHRABCG2NQO2
SCHEMBL2687045 0.76 KDM4E (0.64) KDM4EGAA
SCHEMBL2005467 0.76 PTGS2 (0.46) MTNR1AMTNR1BPTGS2PTGS1AKR1C3
SCHEMBL16312903 0.75 ABCG2 (0.61) MTNR1AMTNR1BABCG2NQO2ADRB2
SCHEMBL24723320 0.75 MTNR1A (0.57) MTNR1AMTNR1BTSHRABCG2NQO2
SCHEMBL10596991 0.75 ALDH1A1 (0.54) MTNR1AMTNR1BPTGS2PTGS1AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3130589-A1 HETEROCYCLIC AZA COMPOUNDS Grünenthal GmbH (DE) 2017-02-15 EP disclosed
EP-2638034-A1 SUBSTITUTED HETEROAROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2013-09-18 EP disclosed
WO-2012062462-A1 SUBSTITUTED HETEROAROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2012-05-18 WO disclosed
WO-2012062462-A1 SUBSTITUTED HETEROAROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2012-05-18 WO disclosed
US-20120115903-A1 Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2012-05-10 US disclosed
US-20120115903-A1 Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2012-05-10 US disclosed
US-20120115903-A1 Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115903-A1 Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands TRPV1, OPRM1, OPRK1 MTNR1A 304/4885MTNR1B 489/4885PTGS2 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.